Adalimumab

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)2.51 [1.06, 5.97]31%5 studies62380not evaluable ROB
Major congenital malformations2.30 [0.94, 5.64]37%4 studies62378not evaluable ROB
2 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)1.17 [0.40, 3.41]0%3 studies42220not evaluable ROB
Small for gestational age (weight)0.80 [0.40, 1.61]0%2 studies30208not evaluable ROB
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Caesarean--0 study
1 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Neonatal infections0.96 [0.41, 2.23]0%2 studies66337not evaluable ROB
1 non statistically significant endpoints reported in only one study

Long term consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)2.39 [0.78, 7.30]0%2 studies32260not evaluable ROB
Elective/induced termination of pregnancy1.95 [0.15, 24.78]0%2 studies1260not evaluable ROB
Therapeutic terminations of pregnancy--0 study
2 non statistically significant endpoints reported in only one study